Geneva Capital Management LLC lessened its stake in shares of STERIS plc (NYSE:STE – Free Report) by 2.8% in the third quarter, HoldingsChannel.com reports. The firm owned 100,773 shares of the medical equipment provider’s stock after selling 2,861 shares during the quarter. Geneva Capital Management LLC’s holdings in STERIS were worth $21,163,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Western Wealth Management LLC bought a new stake in STERIS during the 1st quarter valued at $25,000. Compass Financial Management LLC bought a new stake in STERIS in the 3rd quarter worth $25,000. Elevation Wealth Partners LLC grew its holdings in STERIS by 1,130.0% in the 2nd quarter. Elevation Wealth Partners LLC now owns 123 shares of the medical equipment provider’s stock worth $26,000 after acquiring an additional 113 shares during the last quarter. Trust Co. of Vermont bought a new stake in STERIS in the 2nd quarter worth $41,000. Finally, Community Financial Services Group LLC increased its position in shares of STERIS by 50.0% in the third quarter. Community Financial Services Group LLC now owns 216 shares of the medical equipment provider’s stock valued at $45,000 after acquiring an additional 72 shares during the period. Institutional investors own 94.69% of the company’s stock.
STERIS Stock Down 0.2%
STE stock opened at $263.76 on Monday. STERIS plc has a fifty-two week low of $195.14 and a fifty-two week high of $269.44. The company has a market capitalization of $25.61 billion, a price-to-earnings ratio of 31.29 and a beta of 0.86. The business’s 50 day moving average price is $223.28 and its two-hundred day moving average price is $224.61. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.44 and a current ratio of 2.05.
STERIS (NYSE:STE – Get Free Report) last released its earnings results on Wednesday, November 4th. The medical equipment provider reported $2.94 EPS for the quarter, beating analysts’ consensus estimates of $2.68 by $0.26. The company had revenue of $1.59 billion during the quarter, compared to analysts’ expectations of $1.56 billion. STERIS had a return on equity of 14.80% and a net margin of 13.41%. The firm’s revenue for the quarter was up 8.8% compared to the same quarter last year. During the same quarter last year, the business posted $2.47 EPS. As a group, analysts forecast that STERIS plc will post 11.46 earnings per share for the current fiscal year.
STERIS Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Thursday, December 17th. Investors of record on Tuesday, November 17th will be paid a $0.69 dividend. This represents a $2.76 annualized dividend and a yield of 1.0%. The ex-dividend date of this dividend is Tuesday, November 17th. STERIS’s dividend payout ratio is presently 32.74%.
Analyst Upgrades and Downgrades
STE has been the subject of several recent analyst reports. Jefferies Financial Group raised shares of STERIS from a “hold” rating to a “buy” rating and upped their price objective for the company from $232.00 to $305.00 in a research note on Friday. KeyCorp increased their target price on shares of STERIS from $269.00 to $284.00 and gave the stock an “overweight” rating in a report on Friday, November 6th. UBS Group cut their target price on STERIS from $275.00 to $270.00 and set a “buy” rating on the stock in a research note on Friday, August 7th. Weiss Ratings upgraded STERIS from a “hold (c)” rating to a “hold (c+)” rating in a report on Monday, November 9th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $275.00 price target (up from $270.00) on shares of STERIS in a research report on Friday, August 7th. Five analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $283.50.
Get Our Latest Research Report on STE
Insiders Place Their Bets
In other STERIS news, Director Mohsen Sohi sold 4,893 shares of the stock in a transaction on Tuesday, November 10th. The stock was sold at an average price of $253.22, for a total value of $1,239,005.46. Following the completion of the transaction, the director owned 24,305 shares in the company, valued at approximately $6,154,512.10. This represents a 16.76% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Karen Burton sold 5,880 shares of the firm’s stock in a transaction on Wednesday, November 11th. The shares were sold at an average price of $255.62, for a total value of $1,503,045.60. Following the transaction, the chief financial officer directly owned 12,956 shares of the company’s stock, valued at $3,311,812.72. This represents a 31.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 1.12% of the stock is currently owned by corporate insiders.
STERIS Profile
STERIS plc (NYSE: STE) provides infection prevention and procedural products and services for healthcare, pharmaceutical, research, and other industries. Its offerings include sterilizers, washers and other equipment used to clean and sterilize medical devices and surgical instruments, as well as products for operating rooms and endoscopy procedures. The company also provides equipment installation, maintenance, repair, and training, along with contract sterilization and laboratory testing services.
Further Reading
- Five stocks we like better than STERIS
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding STE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for STERIS plc (NYSE:STE – Free Report).
Receive News & Ratings for STERIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS and related companies with MarketBeat.com's FREE daily email newsletter.
